{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T08:50:18Z","timestamp":1758444618251,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jpeds.2023.113643","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:12:27Z","timestamp":1690567947000},"page":"113643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Postmarketing Safety Surveillance of a Hexavalent Vaccine in the Vaccine Adverse Event Reporting System"],"prefix":"10.1016","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7564-0411","authenticated-orcid":false,"given":"Pedro L.","family":"Moro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2023.113643_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr Infect Dis J"},{"year":"2019","series-title":"General best practice guidelines for immunization. Best practice guidance of the Advisory Committee on Immunization Practices (ACIP)","author":"Ezeanolue","key":"10.1016\/j.jpeds.2023.113643_bib2"},{"year":"2018","series-title":"Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate [meningococcal protein conjugate] and Hepatitis B [recombinant] vaccine). [Package insert]","author":"Food and Drug Administration","key":"10.1016\/j.jpeds.2023.113643_bib3"},{"key":"10.1016\/j.jpeds.2023.113643_bib4","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1542\/peds.2014-4102","article-title":"Immunogenicity, safety and tolerability of a hexavalent vaccine in infants","volume":"136","author":"Marshall","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2023.113643_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/INF.0000000000001405","article-title":"Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in U.S. infants","volume":"36","author":"Block","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jpeds.2023.113643_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/INF.0000000000001406","article-title":"A phase III randomized, doubleblind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months","volume":"36","author":"Vesikari","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jpeds.2023.113643_bib7","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2016.05.054","article-title":"A Phase III randomized, doubleblind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months","volume":"34","author":"Silfverdal","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jpeds.2023.113643_bib8","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1016\/j.vaccine.2017.05.043","article-title":"Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)","volume":"35","author":"Martin\u00f3n-Torres","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jpeds.2023.113643_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.15585\/mmwr.mm6905a5","article-title":"Licensure of a Diphtheria and tetanus toxoids and Acellular pertussis, Inactivated Poliovirus, Haemophilus influenzae type b conjugate, and Hepatitis B vaccine, and Guidance for Use in infants","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jpeds.2023.113643_bib10","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jpeds.2023.113643_bib12","first-page":"52252","article-title":"21 CFR Part 600.80. Postmarketing reporting of adverse experiences","volume":"62","year":"1997","journal-title":"Fed Regist"},{"year":"2011","series-title":"Adverse effects of vaccines: evidence and causality. Institute of Medicine","key":"10.1016\/j.jpeds.2023.113643_bib13"},{"key":"10.1016\/j.jpeds.2023.113643_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and Diphtheria with vaccines in the United States: recommendations of the Advisory Committee on immunization Practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.jpeds.2023.113643_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.jpeds.2023.113643_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jpeds.2023.113643_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants","volume":"370","author":"Yih","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2023.113643_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1311738","article-title":"Risk of intussusception after monovalent rotavirus vaccination","volume":"370","author":"Weintraub","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2023.113643_bib19","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-4171","article-title":"Safety surveillance of Diphtheria and tetanus toxoids and Acellular pertussis (DTaP) vaccines","volume":"142","author":"Moro","year":"2018","journal-title":"Pediatrics"},{"year":"2021","series-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","key":"10.1016\/j.jpeds.2023.113643_bib20"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347623005061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347623005061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:17:43Z","timestamp":1758359863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347623005061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":19,"alternative-id":["S0022347623005061"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2023.113643","relation":{},"ISSN":["0022-3476"],"issn-type":[{"type":"print","value":"0022-3476"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarketing Safety Surveillance of a Hexavalent Vaccine in the Vaccine Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2023.113643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113643"}}